120 related articles for article (PubMed ID: 35981123)
1. Coverage with evidence development: where are we now?
Zeitler EP; Gilstrap LG; Coylewright M; Slotwiner DJ; Colla CH; Al-Khatib SM
Am J Manag Care; 2022 Aug; 28(8):382-389. PubMed ID: 35981123
[TBL] [Abstract][Full Text] [Related]
2. A Roadmap for Improving Medicare's Application of Coverage With Evidence Development.
Lakdawalla D; Tunis S; Neumann P; Whicher D; Zeitler E; Liden B
Value Health; 2024 May; ():. PubMed ID: 38795958
[TBL] [Abstract][Full Text] [Related]
3. How donanemab data address the coverage with evidence development questions.
Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
[TBL] [Abstract][Full Text] [Related]
4. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
[TBL] [Abstract][Full Text] [Related]
5. The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development.
Lindsay MJ; Siegel BA; Tunis SR; Hillner BE; Shields AF; Carey BP; Coleman RE
AJR Am J Roentgenol; 2007 Apr; 188(4):1109-13. PubMed ID: 17377055
[TBL] [Abstract][Full Text] [Related]
6. The National Oncologic PET Registry (NOPR): design and analysis plan.
Hillner BE; Liu D; Coleman RE; Shields AF; Gareen IF; Hanna L; Stine SH; Siegel BA
J Nucl Med; 2007 Nov; 48(11):1901-8. PubMed ID: 17942807
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the Medicare Part D Medication Therapy Management Program from Inception in 2006 to the Present.
Gray C; Cooke CE; Brandt N
Am Health Drug Benefits; 2019 Sep; 12(5):243-251. PubMed ID: 32015791
[TBL] [Abstract][Full Text] [Related]
8. Coverage with evidence development: the Ontario experience.
Levin L; Goeree R; Levine M; Krahn M; Easty T; Brown A; Henry D
Int J Technol Assess Health Care; 2011 Apr; 27(2):159-68. PubMed ID: 21473814
[TBL] [Abstract][Full Text] [Related]
9. How changes in the Medicare coverage process have facilitated the spread of new technologies.
Straube BM
Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-314-W5-316. PubMed ID: 15975989
[TBL] [Abstract][Full Text] [Related]
10. Coverage with Evidence Development: applications and issues.
Trueman P; Grainger DL; Downs KE
Int J Technol Assess Health Care; 2010 Jan; 26(1):79-85. PubMed ID: 20059784
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions.
Dhruva SS; Redberg RF
Arch Intern Med; 2008 Jan; 168(2):136-40. PubMed ID: 18227358
[TBL] [Abstract][Full Text] [Related]
13. Value-based interventional pain management: a review of medicare national and local coverage determination policies.
Manchikanti L; Falco FJ; Benyamin RM; Helm S; Singh V; Hirsch JA
Pain Physician; 2013; 16(3):E145-80. PubMed ID: 23703416
[TBL] [Abstract][Full Text] [Related]
14. Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy.
Carino T; Williams RD; Colbert AM; Bridger P
Health Aff (Millwood); 2006; 25(5):1231-9. PubMed ID: 16966718
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the First Round of Public Comments for the National Coverage Determination for Monoclonal Antibodies in the Treatment of Alzheimer's Disease.
Wahl J; Gadbois EA
J Aging Soc Policy; 2023 Jul; ():1-20. PubMed ID: 37486161
[TBL] [Abstract][Full Text] [Related]
16. Medicare program; Medicare prescription drug benefit. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
[TBL] [Abstract][Full Text] [Related]
17. Summary of the 2018 Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) for transcatheter aortic valve replacement.
Rogers T; Khan JM; Edelman JJ; Waksman R
Cardiovasc Revasc Med; 2018 Dec; 19(8):964-970. PubMed ID: 30344056
[TBL] [Abstract][Full Text] [Related]
18. CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY.
Chambers JD; Chenoweth MD; Pyo J; Cangelosi MJ; Neumann PJ
Int J Technol Assess Health Care; 2015 Jan; 31(5):347-54. PubMed ID: 26750558
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer's Disease.
Morin PJ; Zhang Q; Xia W; Miller D; Querfurth H; Tahami Monfared AA
Neurol Ther; 2023 Jun; 12(3):721-726. PubMed ID: 36933140
[TBL] [Abstract][Full Text] [Related]
20. Assessing clinical benefit in the Medicare Drug Price Negotiation Program: A 2-step approach for improving transparency, consistency, and meaningful patient engagement.
DiStefano MJ; Zemplenyi A; McQueen RB
J Manag Care Spec Pharm; 2024 Mar; 30(3):252-258. PubMed ID: 38241282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
